Next-generation probiotics as a therapeutic strategy for the treatment of phenylketonuria: a review
- 12 May 2022
- journal article
- review article
- Published by Oxford University Press (OUP) in Nutrition Reviews
- Vol. 80 (10) , 2100-2112
Abstract
Phenylketonuria (PKU) is a rare genetic disease that causes brain toxicity due to the inability of the body to convert dietary phenylalanine to tyrosine by the action of phenylalanine hydroxylase. The only treatment for PKU so far is lifelong dietary intervention to ensure normal human growth and neurodevelopment. However, in adults, low long-term adherence to this type of dietary intervention has been observed. Given the important role of the intestinal microbiota in the process of digestion and disease prevention, probiotics could be a therapeutic strategy to help degrade dietary phenylalanine, reducing its levels before ingestion. Genetically modified probiotics designed as live biotherapeutic agents for the treatment of specific diseases are sophisticated alternative therapeutic strategies. In this review, the focus is on demonstrating what has been elucidated so far about the use of next-generation probiotics as a therapeutic strategy in the treatment of individuals with PKU. The results described in the literature are encouraging and use genetically modified engineered probiotics showing efficacy both in vitro and in vivo. These probiotics appear to be suitable for meeting the unmet need for new drugs for PKU.Keywords
This publication has 87 references indexed in Scilit:
- Recombinant Probiotic Expressing Listeria Adhesion Protein Attenuates Listeria monocytogenes Virulence In VitroPLOS ONE, 2012
- PhenylketonuriaThe Lancet, 2010
- Safety assessment of probiotics for human useGut Microbes, 2010
- Immune adaptations that maintain homeostasis with the intestinal microbiotaNature Reviews Immunology, 2010
- Personal Reflections on the Origins and Emergence of Recombinant DNA TechnologyGenetics, 2010
- Converting an injectable protein therapeutic into an oral form: Phenylalanine ammonia lyase for phenylketonuriaMolecular Genetics and Metabolism, 2010
- Quality of life in noncompliant adults with phenylketonuria after resumption of the dietJournal of Inherited Metabolic Disease, 2008
- Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuriaJournal of Clinical Investigation, 2008
- Fenilcetonúria no Brasil: evolução e casosRevista de Nutrição, 2006
- Probiotic and other functional microbes: from markets to mechanismsCurrent Opinion in Biotechnology, 2005